Results 171 to 180 of about 229,435 (354)

Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer [PDF]

open access: bronze, 1994
Judith D. Sears   +3 more
openalex   +1 more source

Prospective evaluation of 92 protein biomarkers for early detection of endometrial cancer

open access: yesInternational Journal of Cancer, EarlyView.
What's New? In this prospective study, the authors evaluated the discrimination capacity of 92 cancer‐related proteins as potential early detection biomarkers for endometrial cancer using blood samples from two large‐scale European population cohorts (EPIC and Janus).
Victoria Cooley   +12 more
wiley   +1 more source

Endometrial carcinoma with trophoblastic differentiation. An aggressive form of uterine cancer [PDF]

open access: bronze, 1991
Carlo Pesce   +3 more
openalex   +1 more source

Comprehensive genetic and epigenetic characterization of Lynch‐like syndrome patients

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Lynch‐like syndrome is associated with development of colorectal cancer (CRC) with microsatellite instability and loss of expression of certain mismatch repair (MMR) genes, similar to Lynch syndrome, but unlike Lynch syndrome, the genetic cause of Lynch‐like syndrome (LLS) remains unknown.
Francesca Pirini   +18 more
wiley   +1 more source

Detection of p53 Gene Mutations in Human Ovarian and Endometrial Cancers by Polymerase Chain Reaction‐Single Strand Conformation Polymorphism Analysis [PDF]

open access: green, 1992
Mariko Fujimoto Naito   +7 more
openalex   +1 more source

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Currently, no published data on homologous recombination deficiency (HRD) testing in the setting of molecular tumor boards exist. This study in a cohort of 237 patients encompassing 24 different tumor entities assessed by a molecular tumor board shows that inactivating alterations of BRCA1/2 are not always associated with an elevated ...
Christoph Schubart   +26 more
wiley   +1 more source

Knockdown of S100A2 inhibits the aggressiveness of endometrial cancer by activating STING pathway

open access: yesJournal of Obstetrics and Gynaecology
Background Endometrial cancer is a kind of gynaecological cancer. S100A2 is a newfound biomarker to diagnose endometrial cancer. This study was to investigate the role of S100A2 on regulating migration and invasion of endometrial cancer.Methods The mRNA ...
Chengcheng Li   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy